FDA Orphan Designation Supports Ofirnoflast as Novel MDS Therapy US FDA Orphan Drug Designation supports continued development of ofirnoflast (HT-6184) for myelodysplasic syndromes (MDS).

The @fda.gov granted #OrphanDrug Designation to #Ofirnoflast (HT-6184) for the treatment of #MyelodysplasticSyndromes (#MDS), recognizing the agent’s potential to address a key upstream mechanism of inflammation-driven bone marrow failure.

Read more: https://bit.ly/48PwfvV

#RareDisease #HT6184